Blue Water Vaccines Inc to Present at World Vaccine Congress Washington 2022
- BWV-101 - Universal Influenza Program: Developing a novel vaccine to protect against all influenza strains using groundbreaking mathematical models and research
CINCINNATI, April 11, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or “the Company”) a biopharmaceutical company developing transformational vaccines to address significant global health challenges, today announced that Brian Price, Ph.D., Head of Technology Strategy, will deliver a presentation during the World Vaccine Congress 2022 in Washington, DC. BWV will present on its universal influenza vaccine candidate, which utilizes the exclusively licensed epitopes of limited variability identified by scientists at The University of Oxford.
Session details are as follows:
|Date:||Wednesday, April 20, 2022|
|Time:||5:55 p.m. Eastern Daylight Time (EDT)|
|Title:||BWV-101 - Universal Influenza Vaccine Program|
|BWV Participant:||Brian Price, Ph.D., Head of Technology Strategy|
“We are honored to present at such a prestigious conference focused on the development of novel vaccines,” said Joseph Hernandez, Chief Executive Officer of Blue Water Vaccines. “In collaboration with The University of Oxford, we are committed to exploring the development of a universal influenza vaccine via epitopes of limited variability and are excited to present our technology to peers from around the world.”
BWV management will be available during the events for one-on-one meetings. Interested parties may request a one-on-one meeting at email@example.com or contact BWV at (513) 620-4101.
About Blue Water Vaccines
Blue Water Vaccines Inc. is a biopharmaceutical company focused on developing transformational vaccines to address significant health challenges globally. Headquartered in Cincinnati, OH, the company holds the rights to proprietary technology developed at the University of Oxford, Cincinnati Children's Hospital Medical Center (CCHMC), and St. Jude Children's Hospital. The company is developing a universal flu vaccine that will provide protection from all virulent strains in addition to licensing a novel norovirus (NoV) S&P nanoparticle versatile virus-like particle (VLP) vaccine platform from CCHMC to develop vaccines for multiple infectious diseases, including norovirus/rotavirus and malaria, among others. Additionally, Blue Water Vaccines is developing a Streptococcus pneumoniae (pneumococcus) vaccine candidate, designed to specifically prevent the highly infectious middle ear infections, known as Acute Otitis Media (AOM), in children. For more information, visit www.bluewatervaccines.com.
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on BWV’s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the development of BWV’s vaccine candidates, including, but not limited to BWV-301; the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; delays and uncertainties caused by the global COVID-19 pandemic; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any vaccine under development, there are significant risks in the development, regulatory approval and commercialization of new products. BWV does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in BWV’s registration statement on Form S-1 relating to its initial public offering, initially filed with the Securities and Exchange Commission (the “SEC”) on October 10, 2021, as amended, and periodic reports filed with the SEC on or after the date thereof. All of BWV’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.